At the time of writing, I am in Turku, Finland at the annual meeting of the Scandinavian Society for the Study of Diabetes. As the name says, this is a Scandinavian meeting for physicians and researchers interested in diabetes. The mayor of Turku opened the meeting with an interesting question: Is there anyone who remembers where the meeting was last year, and the two years before? Uncertain responses. But do you remember someone you met at these meetings and what you talked about? Yes, that was something completely different! Of course we remembered meeting old and new acquaintances, exchange og information and ideas for new studies. Even though today we have very effective tools for sharing information through the internet and other types of computer networks, personal meeting with professionals at home and abroad is more important than ever. It maintains existing and opens up new friendships, and provides professional refills. It is possible that a meeting must have something physical to attract attendees, but I am not so sure that it really means so much. Hence, I’m coming back from a meeting full of enthusiasm and new ideas, and I think little about where the meeting actually took place. So, go to meetings, make new friends and learn something new!
Gilead Sciences Nordics proudly announces the sixth year of the Gilead Sciences Nordic Fellowship Programme. Funding this year will total SEK 3,000,000 to projects executed in the Nordic countries.
The aim of the Gilead Sciences Nordic Fellowship Programme is to award financial grants to encourage the development, exploration and dissemination of new ideas, generating best practice in the delivery of patient-centred care in three areas – HIV, liver diseases (LVD), and hematology/oncology (ONC). Evidence generated from Fellowship projects provides the opportunity to shape public health policy and practice, or to generate new studies or joint ventures to shape clinical care pathways. The projects supported under the Gilead Sciences Nordic Fellowship Programme are independent of the use of any particular therapeutic agent.
Please see the attached brochure for further details about the fellowship program – the topics for this year, the application timeline etc. Also, please note, that proposals that meet the criteria for a clinical trial under the EU Clinical Trials Directive 2001/20/EC cannot be funded under the fellowship program.
Gilead Sciences Nordic is committed to supporting local initiatives which ultimately improve patient care and we look forward to receiving completed applications over the next few months.
Guidance to applicant can be found here.
More information about the nordic fellowship programme can be found here.
If you have any questions then please contact us here.
Anette M. Hommelgaard, PhD
Country Medical Director Nordics Gilead Sciences Nordic
The September 2018 introductory course on Pharmaceutical Bioinformatics (7.5 ECTS credits) given by Uppsala University is now open for application.
The course, which is free of charge for EU/EAA-citizens, is suited for researchers, post docs, teachers and students who are interested to learn how complex chemical and biomedical processes can be investigated even down to their finest chemical details using informatics, and how this can be used for the development of novel drugs.
Further information and signing up can be found here.
On request of many previous participants we now also offer two additional courses:
1. Applied Structural Pharmaceutical Bioinformatis (5 ECTS credits) (course start September 2018).
2. Applied Pharmaceutical Bioinformatics (5 ECTS credits) (course start November 2018)
More information about both courses are available here.
Invited talk by Prof. C. Ronald Kahn, Harvard Medical School.
One of the world’s—if not the world’s—leader in insulin signaling.
Date: Wednesday April 18th
Place: Auditorium @ Armauer Hansens hus, Haukeland University Hospital
A recent study from Prof. Kahn has identified viruses that can produce insulin-like hormones that are active on human cells. This novel discovery brings new possibilities for revealing biological mechanisms that may cause diabetes, as well as autoimmune disease, metabolic conditions or cancer.
Viruses known to infect fish and amphibians, could possibly expose humans to viral insulins. Prof. Kahn and his colleagues at Joslin have found that various viruses can produce peptides that are similar in whole or in part to 16 human hormones and regulatory proteins. Four viruses interestingly have insulin-like sequences, and show ability to bind to and stimulate human insulin receptors and receptors for a closely related hormone called IGF-1 (insulin-like growth factor 1). The viral peptides could this way potentially stimulate all signaling pathways inside the cells that are stimulated by human insulin and IGF-1, including glucose uptake and cellular Growth.